Healthcare Industry News: zolpidem
News Release - April 25, 2007
Dr. Reddy's Announces the Launch of Zolpidem Tartrate Tablets
HYDERABAD, India--(HSMN NewsFeed)--Dr. Reddy's Laboratories (NYSE:RDY ) today announced that the Company has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for zolpidem Tartrate Tablets, 5 mg and 10 mg. This product is being shipped immediately.zolpidem Tartrate Tablets are the generic version of Sanofi-Aventis' Ambien® Tablets. Ambien Tablets had U.S. sales of approximately $2.1 billion for the same strengths for 2006 according to IMS Health.
About Dr. Reddy's
Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY ) is an emerging global pharmaceutical company with proven research capabilities. The Company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of diabetes, cardiovascular, anti-infectives, inflammation and cancer.
Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.
Source: Dr. Reddy's Laboratories
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
